Company / Financials
CUMBERLAND PHARMACEUTICALS INC Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$11.7M
FY2025 · -70.4% YoY
Net Income
$1.3M
FY2025 · +120.0% YoY
Profit Margin
10.7%
FY2025 · net income / revenue
ROE
5.1%
FY2025 · return on equity
Total Assets
$76.8M
FY2025
Total Debt
-
FY2025
Equity
$24.9M
FY2025
ROA
1.6%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$11.7M-70.4% YoYNet Income HistoryProfit after all expenses and taxes$1.3M+120.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$6.7M+9.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes$1.3M+113.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$11.9M+12.2% YoYR&D Expense HistoryResearch and development spending$5.6M-4.6% YoYInterest Expense HistoryCost of borrowing and debt obligations$496.0K-25.7% YoYIncome Tax HistoryTotal income tax expense$40.3K-12.0% YoYEPS (Basic) HistoryBasic earnings per share-$0.46-4.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.46-4.5% YoY